Mga Batayang Estadistika
| LEI | 549300FC27CEJIY52K95 |
| CIK | 1169245 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to PhaseBio Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 30, 2024 |
As filed with the U.S. Securities and Exchange Commission on September 30, 2024 As filed with the U.S. Securities and Exchange Commission on September 30, 2024 Registration No. 333-227935 Registration No. 333-230504 Registration No. 333-237462 Registration No. 333-254268 Registration No. 333-262185 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-227935 POST EFFECTIVE AMENDMENT NO |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38697 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specif |
|
| September 30, 2024 |
As filed with the U.S. Securities and Exchange Commission on September 30, 2024 As filed with the U.S. Securities and Exchange Commission on September 30, 2024 Registration No. 333-227935 Registration No. 333-230504 Registration No. 333-237462 Registration No. 333-254268 Registration No. 333-262185 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-227935 POST EFFECTIVE AMENDMENT NO |
|
| September 30, 2024 |
As filed with the U.S. Securities and Exchange Commission on September 30, 2024 As filed with the U.S. Securities and Exchange Commission on September 30, 2024 Registration No. 333-227935 Registration No. 333-230504 Registration No. 333-237462 Registration No. 333-254268 Registration No. 333-262185 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-227935 POST EFFECTIVE AMENDMENT NO |
|
| September 30, 2024 |
As filed with the U.S. Securities and Exchange Commission on September 30, 2024 As filed with the U.S. Securities and Exchange Commission on September 30, 2024 Registration No. 333-227935 Registration No. 333-230504 Registration No. 333-237462 Registration No. 333-254268 Registration No. 333-262185 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-227935 POST EFFECTIVE AMENDMENT NO |
|
| September 30, 2024 |
As filed with the U.S. Securities and Exchange Commission on September 30, 2024 As filed with the U.S. Securities and Exchange Commission on September 30, 2024 Registration No. 333-227935 Registration No. 333-230504 Registration No. 333-237462 Registration No. 333-254268 Registration No. 333-262185 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-227935 POST EFFECTIVE AMENDMENT NO |
|
| August 15, 2024 |
SEC FILE NUMBER 001-38697 CUSIP NUMBER 717224109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 15, 2024 |
Exhibit 99.1 Case 22-10995-LSS Doc 1144 Filed 07/26/24 Page 1 of 12 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. PHASEBIO PHARMACEUTICALS, INC § Case No. 22-10995 § § Debtor(s) § ☐ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 06/30/2024 P |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2024 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 12, 2024 |
Exhibit 99.1 Case 22-10995-LSS Doc 1087 Filed 05/23/24 Page 1 of 12 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. PHASEBIO PHARMACEUTICALS, INC § Case No. 22-10995 § § Debtor(s) § ☐ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 04/30/2024 Petition Date: 10/23/2022 |
|
| July 12, 2024 |
Case 22-10995-LSS Doc 1064 Filed 05/13/24 Page 1 of 98 Exhibit 2.1 Case 22-10995-LSS Doc 1064 Filed 05/13/24 Page 1 of 98 Solicitation Version IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE ) In re: ) Chapter 11 ) PHASEBIO PHARMACEUTICALS, INC. ) Case No. 22-10995 (LSS) ) Debtor.1 ) ) ) DEBTOR’S FIRST AMENDED COMBINED DISCLOSURE STATEMENT AND CHAPTER 11 PLAN RICHARDS, LAYTON & FINGER, P.A. COOLEY LLP Daniel J. DeFranceschi, Esq. |
|
| July 12, 2024 |
Exhibit 99.2 Case 22-10995-LSS Doc 1119 Filed 06/25/24 Page 1 of 12 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. PHASEBIO PHARMACEUTICALS, INC § Case No. 22-10995 § § Debtor(s) § ☐ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 05/31/2024 Petition Date: 10/23/2022 |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 16, 2024 |
Exhibit 99.1 Case 22-10995-LSS Doc 1004 Filed 03/22/24 Page 1 of 12 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. PHASEBIO PHARMACEUTICALS, INC § Case No. 22-10995 § § Debtor(s) § ☐ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 02/29/2024 Petition Date: 10/23/2022 |
|
| May 16, 2024 |
SEC FILE NUMBER 001-38697 CUSIP NUMBER 717224109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 16, 2024 |
Exhibit 99.2 Case 22-10995-LSS Doc 1040 Filed 04/24/24 Page 1 of 12 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. PHASEBIO PHARMACEUTICALS, INC § Case No. 22-10995 § § Debtor(s) § ☐ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 03/31/2024 Petition Date: 10/23/2022 Months Pending: 18 Industry Classi |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Comm |
|
| April 2, 2024 |
SEC FILE NUMBER 001-38697 CUSIP NUMBER 717224109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 12, 2024 |
Exhibit 99.3 Case 22-10995-LSS Doc 979 Filed 02/23/24 Page 1 of 12 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. PHASEBIO PHARMACEUTICALS, INC § Case No. 22-10995 § § Debtor(s) § ☐ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 01/31/2024 Petition Date: 10/23/2022 Months Pending: 16 Industry Classification: 2 8 3 4 |
|
| March 12, 2024 |
Exhibit 99.1 Case 22-10995-LSS Doc 906 Filed 12/20/23 Page 1 of 12 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. PHASEBIO PHARMACEUTICALS, INC § Case No. 22-10995 § § Debtor(s) § ☐ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 11/30/2023 Petition Date: 10/23 |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 12, 2024 |
Exhibit 99.2 Case 22-10995-LSS Doc 934 Filed 01/25/24 Page 1 of 12 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. PHASEBIO PHARMACEUTICALS, INC § Case No. 22-10995 § § Debtor(s) § ☐ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 12/31/2023 Petition Date: 10/23/2022 Months Pending: 14 In |
|
| March 12, 2024 |
PLAN SUPPORT AND SETTLEMENT AGREEMENT Exhibit 10.1 Execution Version PLAN SUPPORT AND SETTLEMENT AGREEMENT This PLAN SUPPORT AND SETTLEMENT AGREEMENT (together with the schedules attached hereto, as each may be amended, restated, supplemented, or otherwise modified from time to time in accordance with the terms hereof, this “Agreement”), dated as of March 6, 2024, is entered into by and between: (i) PhaseBio Pharmaceuticals, Inc. (“Ph |
|
| November 29, 2023 |
UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. |
|
| November 29, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (C |
|
| November 29, 2023 |
UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. |
|
| November 15, 2023 |
SEC FILE NUMBER 001-38697 CUSIP NUMBER 717224109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) ( |
|
| September 27, 2023 |
UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. |
|
| September 27, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2023 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) ( |
|
| August 25, 2023 |
UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. |
|
| August 25, 2023 |
UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. |
|
| August 25, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 25, 2023 |
SEC FILE NUMBER 001-38697 CUSIP NUMBER 717224109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 30, 2023 |
Case 22-10995-LSS Doc 665 Filed 06/22/23 Page 1 of 12 Case 22-10995-LSS Doc 665 Filed 06/22/23 Page 2 of 12 Aggregate Total Itemized Breakdown by Firm Case 22-10995-LSS Doc 665 Filed 06/22/23 Page 3 of 12 Case 22-10995-LSS Doc 665 Filed 06/22/23 Page 4 of 12 Aggregate Total Itemized Breakdown by Firm Case 22-10995-LSS Doc 665 Filed 06/22/23 Page 5 of 12 Case 22-10995-LSS Doc 665 Filed 06/22/23 Pag |
|
| May 30, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 30, 2023 |
phasqmorapril2023 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. |
|
| May 16, 2023 |
phasebio-nt10xqq12023 SEC FILE NUMBER 001-38697 CUSIP NUMBER 717224109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 10, 2023 |
phasqmormarch2023 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. |
|
| May 10, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 3, 2023 |
phasebio-nt10xk2022final SEC FILE NUMBER 001-38697 CUSIP NUMBER 717224109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 24, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 24, 2023 |
phasebiocase22-10995dock UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. |
|
| February 24, 2023 |
phasqmorjan2023 Case 22-10995-LSS Doc 508 Filed 02/21/23 Page 1 of 12 Case 22-10995-LSS Doc 508 Filed 02/21/23 Page 2 of 12 Aggregate Total Itemized Breakdown by Firm Case 22-10995-LSS Doc 508 Filed 02/21/23 Page 3 of 12 Case 22-10995-LSS Doc 508 Filed 02/21/23 Page 4 of 12 Aggregate Total Itemized Breakdown by Firm Case 22-10995-LSS Doc 508 Filed 02/21/23 Page 5 of 12 Case 22-10995-LSS Doc 508 Fi |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (C |
|
| February 14, 2023 |
PHAS / PhaseBio Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* PhaseBio Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 717224109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 14, 2023 |
PHAS / PhaseBio Pharmaceuticals Inc / Rock Springs Capital Management LP Passive Investment SC 13G/A 1 rocksprings-phas123122a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* PhaseBio Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value, $0.001 per share (Title of Class of Securities) 717224109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this State |
|
| February 14, 2023 |
PHAS / PhaseBio Pharmaceuticals Inc / Avidity Partners Management LP Passive Investment SC 13G/A 1 d994223513g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* PhaseBio Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 717224109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 6, 2023 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* PhaseBio Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 717224109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| January 25, 2023 |
UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. |
|
| January 25, 2023 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2023 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2023 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 17, 2023 |
phasebiosfj-settlementa SETTLEMENT AGREEMENT This Settlement Agreement (including all schedules and exhibits hereto, this “Settlement Agreement”) is entered into this 13th day of January, 2023 (the “Execution Date”), by and between PhaseBio Pharmaceuticals, Inc. |
|
| January 17, 2023 |
sfj-pbxprogramtransferag PROGRAM TRANSFER AGREEMENT THIS PROGRAM TRANSFER AGREEMENT (this “Agreement”) is made and entered into as of January 13, 2023, by and between PhaseBio Pharmaceuticals, Inc. |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2022 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (C |
|
| December 23, 2022 |
docket294-novembermor Case 22-10995-LSS Doc 294 Filed 12/21/22 Page 1 of 12 Case 22-10995-LSS Doc 294 Filed 12/21/22 Page 2 of 12 Aggregate Total Itemized Breakdown by Firm Case 22-10995-LSS Doc 294 Filed 12/21/22 Page 3 of 12 Case 22-10995-LSS Doc 294 Filed 12/21/22 Page 4 of 12 Aggregate Total Itemized Breakdown by Firm Case 22-10995-LSS Doc 294 Filed 12/21/22 Page 5 of 12 Case 22-10995-LSS Doc |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (C |
|
| November 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (C |
|
| November 23, 2022 |
UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. |
|
| November 15, 2022 |
SEC FILE NUMBER 001-38697 CUSIP NUMBER 717224109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 8, 2022 |
EXHIBIT 10.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT BY AND BETWEEN PHASEBIO PHARMACEUTICALS, INC., AND CHIESI FARMACEUTICI S.P.A DATED AS OF NOVEMBER 4, 2022 i TABLE OF CONTENTS ARTICLE I THE ACQUISITION .............................................................................................................. 1 Section 1.1. Acquired Assets .................................................. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Co |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* PhaseBio Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 717224109 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Na |
|
| October 31, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2022 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Co |
|
| October 24, 2022 |
Exhibit 99.1 PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code Bidding Process and Auction Projected to Conclude December 2022 Malvern, PA and San Diego, CA, October 24, 2022 — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovas |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2022 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Co |
|
| October 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2022 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2022 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) ( |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38697 PhaseBio Pharmaceutica |
|
| August 12, 2022 |
EX-99.1 2 phasebioq22022financialres.htm EX-99.1 Exhibit 99.1 PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights Malvern, PA and San Diego, CA, August 12, 2022 — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 12, 2022 |
Corporate Overview August 2022 This presentation includes forward-looking statements. |
|
| August 12, 2022 |
Form of RSU Grant Notice and Award Agreement for 2018 Equity Incentive Plan. Exhibit 10.1 PhaseBio Pharmaceuticals, Inc. RSU Award Grant Notice (2018 Equity Incentive Plan) PhaseBio Pharmaceuticals, Inc. (the ?Company?), pursuant to its 2018 Equity Incentive Plan (the ?Plan?) has awarded to you (the ?Participant?) the number of restricted stock units specified, and on the terms set forth, below (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions |
|
| August 8, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Comm |
|
| July 5, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 20, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 16, 2022 |
Form of RSU Grant Notice and Award Agreement for 2022 Inducement Plan Exhibit 10.2 PhaseBio Pharmaceuticals, Inc. RSU Award Grant Notice (2022 Inducement Plan) PhaseBio Pharmaceuticals, Inc. (the ?Company?), pursuant to its 2022 Inducement Plan (the ?Plan?) has awarded to you (the ?Participant?) the number of restricted stock units specified, and on the terms set forth, below (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions set forth h |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38697 PhaseBio Pharmaceutic |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 16, 2022 |
Form of RSU Grant Notice and Award Agreement for 2018 Equity Incentive Plan. Exhibit 10.1 PhaseBio Pharmaceuticals, Inc. RSU Award Grant Notice (2018 Equity Incentive Plan) PhaseBio Pharmaceuticals, Inc. (the ?Company?), pursuant to its 2018 Equity Incentive Plan (the ?Plan?) has awarded to you (the ?Participant?) the number of restricted stock units specified, and on the terms set forth, below (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions |
|
| May 16, 2022 |
Corporate Overview May 2022 This presentation includes forward-looking statements. |
|
| May 16, 2022 |
Exhibit 99.1 PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights Held successful Type B pre-biologics license application (BLA) meeting with U.S. FDA for future submission of BLA for bentracimab BLA submission for bentracimab is planned for early in the fourth quarter of 2022 and PhaseBio is preparing for commercialization in U.S., if approved Prese |
|
| April 22, 2022 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 4, 2022 |
Exhibit 99.1 PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab Results presented on April 2nd during a Late Breaking Featured Clinical Research Presentation at the American College of Cardiology?s 71st Annual Scientific Session (ACC.22) Trial achieved primary reversal endpoint in older volunteers Bentracimab was well tolerated in the Phase 2b trial, with no drug-related serio |
|
| April 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 24, 2022 |
Exhibit 10.25 AMENDMENT NO. 1 to MASTER SERVICES AGREEMENT This Amendment No. 1 to the Master Services Agreement (the ?Amendment?) is made as of the date of last signature below (the ?Amendment Effective Date?), by and between PhaseBio Pharmaceuticals, Inc. (hereinafter ?PhaseBio?) with a place of business at 1 Great Valley Parkway, Suite 30, Malvern, PA 19355, and BioVectra Inc., having a place o |
|
| March 24, 2022 |
Form of RSU Grant Notice and Award Agreement for 2022 Inducement Plan. Exhibit 10.6 PhaseBio Pharmaceuticals, Inc. RSU Award Grant Notice (2022 Inducement Plan) PhaseBio Pharmaceuticals, Inc. (the ?Company?), pursuant to its 2022 Inducement Plan (the ?Plan?) has awarded to you (the ?Participant?) the number of restricted stock units specified, and on the terms set forth, below (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions set forth h |
|
| March 24, 2022 |
Power of Attorney (included on signature page) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38697 PhaseBio Pharmaceuticals, |
|
| March 24, 2022 |
Corporate Overview March 24, 2022 This presentation includes forward-looking statements. |
|
| March 24, 2022 |
Exhibit 99.1 PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights Achieved key clinical milestones for bentracimab program, with positive results from both the completed Phase 2b trial and interim analysis of the ongoing REVERSE-IT global Phase 3 trial Company remains on track to submit Biologics License Application (BLA) for |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 24, 2022 |
Form of RSU Grant Notice and Award Agreement for 2018 Equity Incentive Plan. EX-10.3 2 ex103-2018equityincentivep.htm EX-10.3 Exhibit 10.3 PhaseBio Pharmaceuticals, Inc. RSU Award Grant Notice (2018 Equity Incentive Plan) PhaseBio Pharmaceuticals, Inc. (the “Company”), pursuant to its 2018 Equity Incentive Plan (the “Plan”) has awarded to you (the “Participant”) the number of restricted stock units specified, and on the terms set forth, below (the “RSU Award”). Your RSU Aw |
|
| March 24, 2022 |
Non-Employee Director Compensation Policy, as amended. Exhibit 10.7 PhaseBio Pharmaceuticals, Inc. Non-Employee Director Compensation Policy As Amended February 24, 2022 Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to PhaseBio Pharmaceuticals, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Emplo |
|
| March 24, 2022 |
Severance Benefit Plan and Form of Participation Agreement, as amended. Exhibit 10.9 PhaseBio Pharmaceuticals, Inc. Severance Benefit Plan Amended and Restated as of March 23, 2022 Section 1.Introduction. The PhaseBio Pharmaceuticals, Inc. Severance Benefit Plan (the ?Plan?) is hereby established by the Board of Directors of PhaseBio Pharmaceuticals, Inc. (the ?Company?) effective upon the IPO Date (as defined below). The purpose of the Plan is to provide for the paym |
|
| February 15, 2022 |
PHAS / PhaseBio Pharmaceuticals Inc / Rock Springs Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of PhaseBio Pharmaceuticals, Inc. |
|
| February 14, 2022 |
PHAS / PhaseBio Pharmaceuticals Inc / Rosalind Advisors, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 PhaseBio Pharmaceuticals, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 717224109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 14, 2022 |
PHAS / PhaseBio Pharmaceuticals Inc / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* PhaseBio Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 717224109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PhaseBio Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 717224109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 1, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 PhaseBio Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 717224109 (CUSIP Number) December 31, 2021 ( |
|
| January 14, 2022 |
As filed with the U.S. Securities and Exchange Commission on January 14, 2022 Registration No. 333- S-8 1 s-8coverpagephasebiox2022s.htm S-8 As filed with the U.S. Securities and Exchange Commission on January 14, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PHASEBIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 03-0375697 (State of Incorp |
|
| January 14, 2022 |
2022 Inducement Plan and Forms of Stock Option Grant Notice and Option Agreement. Exhibit 99.3 PHASEBIO PHARMACEUTICALS, INC. 2022 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: JANUARY 13, 2022 1.General. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under NASDAQ Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under NASDAQ |
|
| December 21, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2021 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (C |
|
| December 21, 2021 |
EX-99.1 2 phasebiopb1046update-draf.htm EX-99.1 PhaseBio Provides Pemziviptadil (PB1046) Program Update Phase 2b trial of pemziviptadil in pulmonary arterial hypertension (PAH) voluntarily ended early by the Company in order to evaluate existing program data and determine next steps forward Company to reprioritize resources and capital towards successful commercialization of bentracimab and advanc |
|
| November 15, 2021 |
EX-99.2 3 a20211114-ahareversexiti.htm EX-99.2 REVERSE-IT Phase 3 Trial: Interim Results Presentation and Roundtable Discussion November 15, 2021 Introduction and Corporate Update Jonathan Mow Chief Executive Officer, PhaseBio This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regardin |
|
| November 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events k UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) |
|
| November 15, 2021 |
EX-99.1 2 reverse-itahainterimanalys.htm EX-99.1 PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding Global Phase 3 trial of bentracimab achieved primary reversal endpoint with immediate and sustained reversa |
|
| November 12, 2021 |
424B5 1 d234868d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-235735 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED JANUARY 8, 2020) $55,000,000 Common Stock This prospectus supplement relates to the offer, issuance and sale from time to time of our common stock having an aggregate offering price of up to $55,000,000 through William Blair & Company, L.L.C., re |
|
| November 10, 2021 |
EX-99.1 2 phasebioq32021financialsx.htm EX-99.1 PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights Announced topline data from Phase 2b clinical trial of bentracimab, which was conducted in healthy, older volunteers 50-80 years old Reached interim enrollment milestone for the REVERSE-IT Phase 3 trial of bentracimab Prespecified interim analysis of pivotal REVERSE- |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38697 PhaseBio Pharmace |
|
| November 10, 2021 |
k UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) |
|
| November 10, 2021 |
Exhibit 10.2 PHASEBIO PHARMACEUTICALS, INC. $55,000,000 Shares Common Stock ($0.001 par value) Equity Distribution Agreement November 10, 2021 William Blair & Company, L.L.C. 150 North Riverside Plaza Chicago, Illinois 60606 Ladies and Gentlemen: PhaseBio Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the ?Company?), confirms its agreement (this ?Agreement?) with Willia |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* PhaseBio Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 717224109 (CUSIP Number) October 29, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| November 10, 2021 |
Corporate Overview November 2021 This presentation includes forward-looking statements. |
|
| November 10, 2021 |
2018 Equity Incentive Plan (as amended) EX-10.1 3 a2018equityincentiveplanas.htm EX-10.1 PhaseBio Pharmaceuticals, Inc. 2018 Equity Incentive Plan Adopted by the Board of Directors: October 4, 2018 Approved by the Stockholders: October 4, 2018 IPO Date: October 17, 2018 Amended by the Board of Directors: April 22, 2021 Approved by the Stockholders: June 3, 2021 1. General. (a) Successor to and Continuation of Prior Plan. The Plan is int |
|
| November 3, 2021 |
EX-99.1 2 bentracimabphase2btopliner.htm EX-99.1 PhaseBio Announces Topline Results from Phase 2b Trial for Bentracimab Trial achieved primary reversal endpoint in healthy, older volunteers Safety and efficacy profile of bentracimab in the Phase 2b trial consistent with previously completed Phase 1 and Phase 2a trials Interim results from REVERSE-IT Phase 3 trial to be presented on November 15th a |
|
| November 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 15, 2021 |
PhaseBio Appoints William D. Humphries to Board of Directors PhaseBio Appoints William D. Humphries to Board of Directors Malvern, PA and San Diego, CA, September 15, 2021 ? PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of William D. Humphries to its board of directors. Additionally, Ju |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2021 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) ( |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38697 PhaseBio Pharmaceutica |
|
| August 12, 2021 |
8-K 1 a8-kx81221.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdicti |
|
| August 12, 2021 |
EX-99.1 2 phasebioq22021financialsd.htm EX-99.1 PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights Entered exclusive licensing agreement with Alfasigma S.p.A with up to $245 million in milestone payments and tiered royalty payments for development and commercialization of bentracimab in European and other key markets Achieved interim enrollment milestone with fir |
|
| August 12, 2021 |
EX-99.2 3 phasebiocorporateovervie.htm EX-99.2 Corporate Overview August 2021 This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”), our business strategy and plans, the p |
|
| August 12, 2021 |
EX-99.3 4 phasebiointerimanalysisenr.htm EX-99.3 PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor First 143 patients enrolled in the pivotal Phase 3 trial, with top-line results from interim analysis expected later this y |
|
| August 12, 2021 |
EX-10.2 3 phasebio-medimmuneacknowle.htm EX-10.2 Exhibit 10.2 Certain portions of this exhibit (indicated by “[***]”) have been excluded pursuant to Item 601(b)(10) of Regulation S-K because they are both not material and are the type that the registrant treats as private or confidential. ACKNOWLEDGMENT OF GRANT OF A SUBLICENSE IN ACCORDANCE WITH THE LICENSE AGREEMENT BETWEEN MEDIMMUNE LIMITED AND |
|
| August 12, 2021 |
Exhibit 10.1 Certain portions of this exhibit (indicated by “[***]”) have been excluded pursuant to Item 601(b)(10) of Regulation S-K because they are both not material and are the type that the registrant treats as private or confidential. LICENSE AGREEMENT between ALFASIGMA S.P.A. and PHASEBIO PHARMACEUTICALS, INC. Dated as of June 16, 2021 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 ARTICLE |
|
| August 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 10, 2021 |
EX-99.1 2 ex991-8xkx81021.htm EX-99.1 Exhibit 99.1 PhaseBio Pharmaceuticals and SFJ Pharmaceuticals® Announce Approval of IND Application in China for Bentracimab Enrollment in the REVERSE-IT global Phase 3 trial from clinical sites in China expected to begin later in 2021 MALVERN, PA & SAN DIEGO, CA – August 10, 2021- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutic |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* PhaseBio Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 717224109 (CUSIP Number) July 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| June 17, 2021 |
8-K 1 a8-kx61721.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 PhaseBio Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction |
|
| June 17, 2021 |
Exhibit 99.1 PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab Agreement provides PhaseBio with $20 million upfront payment and eligibility to receive up to $245 million in development and commercial milestones in addition to tiered double digit royalties on sales Collaboration reinforces global bentracimab opportunity Establishes accessibili |
|
| June 4, 2021 |
Submission of Matters to a Vote of Security Holders 8-K 1 a8-kx6321votingresults.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other J |
|
| May 19, 2021 |
EX-99.A 2 exa.htm EXHIBIT A Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of PhaseBio Pharmaceuticals, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: /s/ Steven Salamon Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: /s/ Mike McDo |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 PhaseBio Pharmaceuticals, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 717224109 (CUSIP Number) May 12, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| May 13, 2021 |
EX-99.1 2 ex991-earningsrelease2021q1.htm EX-99.1 Exhibit 99.1 PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights Continued enrollment progress in Phase 3 REVERSE-IT clinical trial for Bentracimab Signed commercial supply agreement with BioVectra to support development and commercialization of lead product candidate bentracimab Completed underwritten public offeri |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 13, 2021 |
EX-99.2 3 phasebiocorporateovervie.htm EX-99.2 Corporate Overview May 2021 Exhibit 99.2 This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”), our business strategy and pl |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38697 PhaseBio Pharmaceutic |
|
| May 13, 2021 |
Bio Pharmaceuticals, Inc. and BioVectra, Inc. EX-10.2 2 ex102-phas10xq2021q1.htm EX-10.2 Exhibit 10.2 Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential. Supply Agreement This Supply Agreement (the “Agreement”) is as entered into as of this 10th day of March, 2021 (“Effective Date”) between PhaseBio Ph |
|
| April 29, 2021 |
DEF 14A 1 proxy2021.htm DEF 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ý Filed by a Party other than the Registrant ☐ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy Statement ¨ Defin |
|
| March 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PhaseBio Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 717224109 (CUSIP Number) March 18, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| March 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 19, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 a8-kxoffering.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2021 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdic |
|
| March 19, 2021 |
16,000,000 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-235735 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED JANUARY 8, 2020) 16,000,000 Shares Common Stock We are offering 16,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the trading symbol “PHAS.” On March 18, 2021, the last reported sale price of our common stock on The Nasdaq Globa |
|
| March 19, 2021 |
PhaseBio Announces Pricing of Public Offering of Common Stock EX-99.1 4 ex991-8xkoffering.htm EX-99.1 Exhibit 99.1 PhaseBio Announces Pricing of Public Offering of Common Stock MALVERN, Pa. and SAN DIEGO, March 17, 2021 – PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the pricing of an underwritten publi |
|
| March 19, 2021 |
Underwriting Agreement, dated March 17, 2021 EX-1.1 2 ex11-offering.htm EX-1.1 Exhibit 1.1 PhaseBio Pharmaceuticals, Inc. 16,000,000 Shares Common Stock ($0.001 par value) Underwriting Agreement New York, New York March 17, 2021 Cowen and Company, LLC Stifel, Nicolaus & Company, Incorporated As Representatives of the several Underwriters, c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Stifel, Nicolaus & Company, |
|
| March 17, 2021 |
SUBJECT TO COMPLETION, DATED MARCH 17, 2021 424B5 1 d85296d424b5.htm 424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying base prospectus are not an offer to sell these securities and are |
|
| March 15, 2021 |
EX-99.1 2 ex991-earningsrelease31521.htm EX-99.1 Exhibit 99.1 PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights Update on Phase 3 REVERSE-IT trial - enrollment ahead of schedule Provides overview of bentracimab development program during virtual Investor & Analyst Day, March 15, 2021, 12-2 pm ET Announced commercial supply agreement with BioVectra |
|
| March 15, 2021 |
Non-Employee Director Compensation Policy, as amended EX-10.3 2 ex103-phas10xk2020.htm EX-10.3 Exhibit 10.3 PhaseBio Pharmaceuticals, Inc. Non-Employee Director Compensation Policy As Amended February 9, 2021 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to PhaseBio Pharmaceuticals, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the |
|
| March 15, 2021 |
Power of Attorney (included on the signature page of this Form S-8) As filed with the U.S. Securities and Exchange Commission on March 15, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PHASEBIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 03-0375697 (State or other jurisdiction of incorporation or organizati |
|
| March 15, 2021 |
EX-99.2 3 ex992-update.htm EX-99.2 Bentracimab Program Update MARCH 15, 2021 This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”), our business strategy and plans, the pr |
|
| March 15, 2021 |
8-K 1 a8-kxearningsrelease31521.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Ot |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38697 PhaseBio Pharmaceuticals, |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 11, 2021 |
EX-99.1 2 ex991-31121.htm EX-99.1 Exhibit 99.1 PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab Malvern, PA and San Diego, CA - March 11, 2021 - PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 28, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2021 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 28, 2021 |
EX-99.1 2 ex991-12821.htm EX-99.1 Exhibit 99.1 PhaseBio Announces Dosing of First Patient in European Union as Part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor Cardiovascular disease remains a leading cause of mortality in both the European Union and globally, with antiplatelet therapy being a core treatment to prevent cardiovascular events |
|
| January 27, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2021 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 27, 2021 |
Exhibit 99.1 PhaseBio Presents Data from Phase 1b/2a Trial of Pemziviptadil for the Treatment of Pulmonary Arterial Hypertension at 15th Pulmonary Vascular Research Institute Virtual World Congress New data for pemziviptadil (PB1046) support continued evaluation as a potential novel therapy of once-weekly VIP analogue for adults with pulmonary arterial hypertension; novel agent observed to be well |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* PhaseBio Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 717224109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| November 16, 2020 |
PHAS / PhaseBio Pharmaceuticals Inc / Rock Springs Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 12, 2020 |
phasebiocorporateovervie Corporate Overview November 2020 Legal Disclaimer This presentation includes forward-looking statements. |
|
| November 12, 2020 |
Exhibit 99.1 PhaseBio Reports Recent Business Highlights and Third-Quarter 2020 Financial Results Expanded pivotal Phase 3 REVERSE-IT trial of product candidate bentracimab (PB2452) for reversal of antiplatelet effects of ticagrelor into Canada and dosed first patients outside the United States Resuming enrollment in ongoing Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertensi |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (C |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38697 PhaseBio Pharmace |
|
| October 23, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Co |
|
| October 23, 2020 |
Exhibit 99.1 PhaseBio Provides Pemziviptadil (PB1046) Program Update VANGARD trial discontinued due to evolving COVID-19 treatment landscape, recent feedback from FDA regarding regulatory and development path, and interim analysis of trial data Enrollment expected to resume for ongoing Phase 2b trial of pemziviptadil in pulmonary arterial hypertension (PAH) Malvern, PA and San Diego, CA - October |
|
| October 6, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Com |
|
| October 6, 2020 |
Exhibit 99.1 PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of Ticagrelor Cardiovascular disease remains a leading cause of mortality in both Canada and globally; the lack of reversal agents for patients taking antiplatelet therapies who require urgent surgery or experience a major bleeding event remain |
|
| August 11, 2020 |
Exhibit 99.1 PhaseBio Reports Recent Business Highlights and Second-Quarter 2020 Financial Results Received FDA authorization to proceed with "VANGARD" clinical trial to assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS) and commenced dosing of patients Malvern, PA, and San Diego, C |
|
| August 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38697 PhaseBio Pharmaceutica |
|
| August 11, 2020 |
EX-99.2 3 phasebiocorporateovervie.htm EX-99.2 Corporate Overview August 2020 Legal Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”) our business strategy |
|
| July 16, 2020 |
Exhibit 99.1 PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients Recently launched Phase 2 "VANGARD" trial to assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome PB1046, a long-acting analog of vasoactive intestinal peptide (V |
|
| July 16, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 5, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 27, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 27, 2020 |
EX-99.1 2 ex991-vangardstudy.htm EX-99.1 Exhibit 99.1 PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients PhaseBio receives clearance of IND application from U.S. FDA under Coronavirus Treatment Acceleration Program (CTAP) "VANGARD" trial will assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical |
|
| May 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 12, 2020 |
phasebiocorporateovervie Corporate Overview May 2020 Legal Disclaimer This presentation includes forward-looking statements. |
|
| May 12, 2020 |
Exhibit 99.1 PhaseBio Reports First Quarter 2020 Financial Results and Recent Business Highlights Initiated PB2452 Phase 3 Trial for the Reversal of the Antiplatelet Effects of Ticagrelor Malvern, PA, and San Diego, CA - May 12, 2020 - PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ca |
|
| May 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38697 PhaseBio Pharmaceutic |
|
| April 24, 2020 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 30, 2020 |
Description of PhaseBio Pharmaceuticals, Inc. Common Stock Exhibit 4.11 DESCRIPTION OF PHASEBIO PHARMACEUTICALS, INC. COMMON STOCK The following description of the common stock of PhaseBio Pharmaceuticals, Inc., or the Company, is a summary and does not purport to be complete. This summary is qualified in its entirety by reference to the provisions of the Delaware General Corporation Law, or the DGCL, and the complete text of the Company’s amended and res |
|
| March 30, 2020 |
Exhibit 10.13 AMENDMENT TO LICENSE AGREEMENT BETWEEN MEDIMMUNE LIMITED AND PHASEBIO PHARMACEUTICALS, INC. This Amendment to License Agreement (“Amendment”) is made and entered into as of January 9, 2020 (the “Amendment Date”), by and between MedImmune Limited, a limited liability company formed under the laws of the United Kingdom (“MedImmune”), and PhaseBio Pharmaceuticals, Inc., a corporation fo |
|
| March 30, 2020 |
Power of Attorney (included on the signature page of this Form S-8) As filed with the U.S. Securities and Exchange Commission on March 30, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PHASEBIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 03-0375697 (State or other jurisdiction of incorporation or organizati |
|
| March 30, 2020 |
Exhibit 4.10 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, |
|
| March 30, 2020 |
EX-10.22 9 ex1022-10xk2019.htm EXHIBIT 10.22 Exhibit 10.22 Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. PROGRAM TRANSFER AGREEMENT THIS PROGRAM TRANSFER AGREEMENT (this “Agreement”) is made and entered into as of [insert date that the Program Transfer Noti |
|
| March 30, 2020 |
Exhibit 10.18 Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement (“Agreement”) is entered into as of March 19, 2020, by and among (a) SILICON VALLEY BANK, a California corpora |
|
| March 30, 2020 |
Exhibit 10.23 Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. CONFIDENTIAL EXECUTION COPY ASSET PURCHASE AGREEMENT by and among PHASEBIO PHARMACEUTICALS, INC., SELENITY THERAPEUTICS (BERMUDA), LTD. and VIAMET PHARMACEUTICALS HOLDINGS, LLC Dated as of January |
|
| March 30, 2020 |
Exhibit 10.21 Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXECUTION VERSION CO-DEVELOPMENT AGREEMENT This Co-Development Agreement (“Agreement”), made effective as of January 9, 2020 (the “Effective Date”), is by and between PhaseBio Pharmaceuticals Inc., |
|
| March 30, 2020 |
PHAS / PhaseBio Pharmaceuticals Inc 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38697 PhaseBio Pharmaceuticals, |
|
| March 30, 2020 |
phasebiocorporateoverc5e Corporate Overview March 2020 Legal Disclaimer This presentation includes forward-looking statements. |
|
| March 30, 2020 |
Exhibit 10.16 CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS CONSENT AND FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of March 19, 2020, by and among (a) SILICON VALLEY BANK, a California corporation (“SVB” or “Bank”), in its capacity as administrative agent and collateral agent (“Agent”), (b) SVB as a lender, (c) WESTRIVER INNOVATION LENDIN |
|
| March 30, 2020 |
Exhibit 99.1 PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights Recently Initiated PB2452 Phase 3 Trial for the Reversal of the Antiplatelet Effects of Ticagrelor Received FDA Breakthrough Therapy Designation and EMA Prime Designation for PB2452 Secured PB2452 Financing and Co-Development Collaboration with SFJ Pharmaceuticals® Malvern, PA |
|
| March 30, 2020 |
Exhibit 10.17 SUBORDINATION AGREEMENT THIS SUBORDINATION AGREEMENT (as may be amended, modified, restated, amended and restated, replaced or supplemented from time to time, this “Agreement”), is entered into as of March 19, 2020 (the “Effective Date”), by and between SILICON VALLEY BANK, a California corporation, in its capacity as administrative agent and collateral agent (“Senior Agent”) under t |
|
| March 20, 2020 |
8-K 1 a8-kxsvbconsent.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisd |
|
| March 4, 2020 |
phasebiocorporateovervie Corporate Overview March 4, 2020 Legal Disclaimer This presentation includes forward-looking statements. |
|
| March 4, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a8-kxcorporatepresentation.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Ot |
|
| February 14, 2020 |
PHAS / PhaseBio Pharmaceuticals Inc / Rock Springs Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2020 |
PhaseBio Appoints Alex C. Sapir to Board of Directors EX-99.1 3 ex991-bodappointment.htm EXHIBIT 99.1 Exhibit 99.1 PhaseBio Appoints Alex C. Sapir to Board of Directors Malvern, PA and San Diego, CA, February 13, 2020 - PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Alex C. Sap |
|
| February 13, 2020 |
Non-Employee Director Compensation Policy, as amended. Exhibit 10.1 PhaseBio Pharmaceuticals, Inc. Non-Employee Director Compensation Policy As Amended February 12, 2020 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to PhaseBio Pharmaceuticals, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Emplo |
|
| February 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (C |
|
| February 11, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (C |
|
| February 11, 2020 |
Exhibit 99.1 PhaseBio Announces European Regulatory Update for PB2452 PB2452 granted PRIME Designation by the European Medicines Agency PhaseBio receives written scientific advice confirming PB2452 clinical development plan In Phase 1 and Phase 2a clinical trials, PB2452 provided immediate and sustained reversal of the antiplatelet effects of ticagrelor Malvern, PA and San Diego, CA, February 11, |
|
| February 4, 2020 |
Exhibit 99.1 PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data Presented at 14th Pulmonary Vascular Research Institute World Congress Data continue to support potential of once-weekly VIP analogue for adults with pulmonary arterial hypertension Malvern, PA and San Diego, CA, February 4, 2020 - PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical compan |
|
| February 4, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 27, 2020 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* PhaseBio Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 717224109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| January 17, 2020 |
SC 13G/A 1 s13gaphasebio-011620.htm SCHEDULE 13G FOR PHASEBIO PHARMACEUTICALS, INC. BY JOHNSON & JOHNSON, DATED 12.31.19 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 PhaseBio Pharmaceuticals, Inc. (N |
|
| January 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Com |
|
| January 13, 2020 |
EX-99.1 2 ex991-6440announcement.htm EXHIBIT 99.1 Exhibit 99.1 PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension PhaseBio to be responsible for all development, manufacturing and commercialization Malvern, PA and San Diego, CA, January 13, 2020 - PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutic |
|
| January 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2020 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Com |
|
| January 10, 2020 |
Exhibit 99.1 PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452 PhaseBio to receive up to $120 million in development funding PhaseBio retains exclusive worldwide commercial rights to PB2452 Malvern, PA and San Diego, CA, January 10, 2020 - PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the develo |
|
| January 6, 2020 |
PHAS / PhaseBio Pharmaceuticals Inc CORRESP - - CORRESP PHASEBIO PHARMACEUTICALS, INC. 11260 El Camino Real, Suite 100 San Diego, CA 92130 January 6, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Paul Fischer RE: PhaseBio Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-235735 Acceleration Request Requested Date: January 8, 202 |
|
| December 27, 2019 |
Form of Indenture, between the Registrant and one or more trustees to be named. EX-4.2 Exhibit 4.2 PHASEBIO PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Cer |
|
| December 27, 2019 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.5 Exhibit 4.5 PHASEBIO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF PHASEBIO PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between PHASEBIO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking a |
|
| December 27, 2019 |
EX-1.2 Exhibit 1.2 PHASEBIO PHARMACEUTICALS, INC. $60,000,000 Shares Common Stock ($0.001 par value) Equity Distribution Agreement December 27, 2019 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 William Blair & Company, L.L.C. 150 North Riverside Plaza Chicago, Illinois 60606 Ladies and Gentlemen: PhaseBio Pharmaceuticals, Inc., a corporation organized under the laws |
|
| December 27, 2019 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.6 Exhibit 4.6 PHASEBIO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF PHASEBIO PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this Agreement), dated as of [●], between PHASEBIO PHARMACEUTICALS, INC., a Delaware corporation (the Company), and [●], a [corporation] [national banking a |
|
| December 27, 2019 |
PHAS / PhaseBio Pharmaceuticals Inc S-3 - - S-3 S-3 Table of Contents As filed with the Securities and Exchange Commission on December 27, 2019 Registration No. |
|
| December 27, 2019 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.4 4 d855727dex44.htm EX-4.4 Exhibit 4.4 PHASEBIO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF PHASEBIO PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between PHASEBIO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [n |
|
| November 14, 2019 |
EX-4.8 6 phas-ex4836.htm EX-4.8 Exhibit 4.8 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANC |
|
| November 14, 2019 |
Exhibit 4.9 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, S |
|
| November 14, 2019 |
PHAS / PhaseBio Pharmaceuticals Inc 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38697 PhaseBio Pharmace |
|
| November 14, 2019 |
Exhibit 99.1 PhaseBio Reports Third Quarter 2019 Financial Results and Recent Corporate Progress Received Written End-of-Phase 1 Meeting Minutes Outlining Clear Development Path for PB2452 Completed Phase 2a Trial of PB2452 in Older and Elderly Subjects on Dual Antiplatelet Therapy Initiated Registrational Phase 2b Trial of PB2452 in Older and Elderly Subjects on Dual Antiplatelet Therapy Malvern, |
|
| November 14, 2019 |
Corporate Overview Fourth Quarter 2019 Exhibit 99.2 Legal Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”) our business strategy and plans, the preclinical |
|
| November 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2019 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (C |
|
| October 15, 2019 |
Exhibit 99.1 PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor Malvern, PA, and San Diego, CA, October 15, 2019 — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced |
|
| October 15, 2019 |
Financial Statements and Exhibits 8-K 1 phas-8k20191015.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2019 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Juri |
|
| September 24, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2019 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) ( |
|
| September 24, 2019 |
Exhibit 99.1 PhaseBio Announces Completion of Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor Preliminary Results from Supratherapeutic-Dose Ticagrelor Cohort Are Consistent with Earlier Phase 2a Cohorts and Previously Published Phase 1 Trial Malvern, PA, and San Diego, CA, September 24, 2019 — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical- |
|
| August 14, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2019 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 14, 2019 |
Exhibit 99.3 PhaseBio Announces Receipt of Minutes of End-of-Phase 1 Meeting with the FDA and Alignment on a Single, Non-Randomized Phase 3 Trial to Support BLA Submission for PB2452 Clinical development plan and Accelerated Approval regulatory path confirmed Phase 3 trial to initiate in the first quarter of 2020 and intended to support both major bleeding and surgery indications Conference call a |
|
| August 14, 2019 |
phas-ex992_14.pptx.htm Corporate Overview August 2019 Exhibit 99.2 Legal Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”) our business strategy and plans, |
|
| August 14, 2019 |
End of Phase 1 Meeting Update August 14, 2019 Exhibit 99.1 Legal Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”) our business strategy and plans, the prec |
|
| August 14, 2019 |
PHAS / PhaseBio Pharmaceuticals Inc 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38697 PhaseBio Pharmaceutica |
|
| August 14, 2019 |
Exhibit 4.6 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, S |
|
| August 14, 2019 |
Exhibit 4.7 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, S |
|
| August 13, 2019 |
Exhibit 99.1 PhaseBio Reports Second Quarter 2019 Financial Results and Recent Corporate Progress Reported positive preliminary results from Phase 2a trial of PB2452 Received FDA Breakthrough Therapy designation for PB2452 Completed underwritten public offering of common stock that raised $46.3 million in net proceeds Malvern, PA and San Diego, CA, August 13, 2019 — PhaseBio Pharmaceuticals, Inc. |
|
| August 13, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2019 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Com |
|
| July 29, 2019 |
EX-99.7.01 Exhibit 7.01 JOINT FILING AGREEMENT Joint Filing Agreement, dated as of July 29, 2019, is by and among the signatories below. Each of the signatories below may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D with respect to shares of Common Stock, par value $0.001 per share, of PhaseBio Pharmaceuticals, Inc., beneficially owned b |
|
| July 29, 2019 |
EX-99.7.02 Exhibit 7.02 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Clay B. Thorp with full power to act singly, his or her true and lawful attorney-in-fact, with full power of substitution, to: (i) sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed |
|
| July 29, 2019 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* PHASEBIO PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 717224109 (CUSIP Number) Clay B. Thorp Hatteras Venture Partners 280 S. Mangum Street, Suite 350 Durham, North Carolina 27701 |
|
| July 1, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2019 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commis |
|
| July 1, 2019 |
PhaseBio Added to Russell 2000® and 3000® Indexes Exhibit 99.1 PhaseBio Added to Russell 2000® and 3000® Indexes Malvern, PA, and San Diego, CA, July 1, 2019 — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that the company has been added to the Russell 2000® and 3000® Indexes, effective after U.S. ma |
|
| June 17, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2019 PhaseBio Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38697 03-0375697 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 17, 2019 |
EX-99.1 2 phas-ex9916.htm EX-99.1 Exhibit 99.1 PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects Top-Line Data Are Consistent with Previously Published Phase 1 Trial Malvern, PA, and San Diego, CA, March 17, 2019 — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical- |
